Solid Biosciences NASDAQ: SLDB plans to meet with the U.S. Food and Drug Administration before the end of 2026 to discuss a potential accelerated approval pathway for its Duchenne muscular dystrophy gene therapy, CEO Bo Cumbo said at a Jefferies fireside chat.
The company has dosed 53 patients with the therapy, SGT-003, and started a Phase 3 study, Cumbo said. Solid also expects to release initial data from its Friedreich’s ataxia program in the first quarter of 2027 and discuss a potential registrational trial with the FDA around the first or second quarter.
Duchenne data and FDA meeting
Cumbo said Solid will bring safety data from all 53 dosed patients to the FDA meeting, along with at least one year of functional data from approximately 12 or slightly more patients. The company has submitted its briefing book but is still analyzing portions of the data, he said.
Solid plans to present the results to the FDA first and share them with investors and patients after receiving the meeting minutes. The package includes measures such as time to rise, a 10-meter run or walk, and the North Star Ambulatory Assessment, as well as biological data including microdystrophin expression, Cumbo said.
Because the study is open-label, Solid is also using an ankle-monitor measure known as stride velocity 95th centile to supplement its functional assessments. Cumbo said the digital measure could help address concerns about bias, coaching or human error if it points in the same direction as other assessments.
Cumbo outlined three potential outcomes from the FDA discussion: the agency could support moving toward a filing, request additional data, or direct the company to finish its Phase 3 study. He said he did not expect the third outcome, while acknowledging that the company must discuss the data with regulators.
If the FDA requests more follow-up, Solid expects to have roughly 30 patients with one year of data by the end of 2026, Cumbo said. The company could then prepare an updated data cut and seek another meeting.
He said that, if the FDA meeting is favorable and everything proceeds smoothly, Solid could complete a biologics license application filing by mid-2027. That timing remains conditional on the regulatory discussion.
Phase 3 enrollment and safety
Solid is not disclosing Phase 3 enrollment figures until the study is fully enrolled, Cumbo said. The trial currently has sites in Canada and Australia, with additional European countries and U.S. sites expected to open late in the current quarter or early in the following quarter.
Once European sites open, the company expects full enrollment to take about 18 months, although it hopes to move faster, he said.
Cumbo said the company had not observed drug-induced liver injury, myocarditis or TMA/aHUS among the 53 patients dosed with SGT-003. Patients received a 30-day steroid regimen without additional immune-suppression drugs, he said.
Friedreich’s ataxia and spending priorities
Solid has dosed five patients in its Friedreich’s ataxia program. Cumbo said the initial data release will focus first on safety in patients with severe disease and may also include functional measures and observations on speech.
The therapy uses systemic administration alongside MRI-guided delivery to the dentate nucleus, Cumbo said. Solid plans to discuss a double-blind, placebo-controlled registrational study with the FDA. He said the company does not yet have all the functional data assembled and that its confidence partly reflects anecdotal comments from physicians, investigators and families.
Solid has slowed its CPVT program and held back an investigational new drug filing for a dilated cardiomyopathy program to focus resources on Duchenne and Friedreich’s ataxia, Cumbo said. The company had $350 million in cash at the end of the third quarter, which he said would fund operations into 2028.
About Solid Biosciences (NASDAQ:SLDB)
Solid Biosciences is a biotechnology company developing genetic medicines for Duchenne muscular dystrophy and other serious neuromuscular and cardiac diseases. The company's research focuses on gene-transfer approaches intended to address underlying causes of these conditions. Its lead program, SGT-003, is an investigational gene therapy being developed for Duchenne muscular dystrophy. Solid Biosciences also has research programs targeting other rare diseases. These programs are in development, and its therapies have not been established as approved treatments.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Solid Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.
While Solid Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.